CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program and that the Company will transition to new commercial leadership as it enters its next phase of growth. “Today we announced two important decisions, both of which demonstrate our conviction in Alnylam’s future,” said Amy Schulman, Chair of Alnylam’s Board of Directors. “Alnylam ha
